Home › Trials › NCT04921553

Registry for patients with rare cancer gene fusions in Europe

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Observational Centre Leon Berard · NCT04921553

This study is creating a registry to track how patients with rare cancer gene fusions, like NTRK, are treated and how their quality of life changes over time.

Quick facts

Study typeObservational
Enrollment500 (estimated)
Ages18 Years and up
SexAll
SponsorCentre Leon Berard Academic / other
Locations41 sites (Graz and 40 other locations)
Trial IDNCT04921553 on ClinicalTrials.gov

What this trial studies

This registry aims to document the real-life management of patients with rare actionable fusions in cancer, focusing on NTRK and other gene mutations. It involves collecting clinical data from medical files and administering a quality of life questionnaire (QLQ-C30) at the time of inclusion, during new treatments, and every six months thereafter. Patients will be followed for at least two years to better understand their treatment outcomes and quality of life. The initiative is a collaborative effort across European centers to enhance data sharing and improve patient management.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with histologically-confirmed cancer harboring a rare actionable fusion.

Not a fit: Patients without a rare actionable fusion or those under 18 years old may not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could lead to improved treatment strategies and better quality of life for patients with rare actionable fusions in cancer.

How similar studies have performed: Other studies focusing on registries for rare cancers have shown promise in improving patient outcomes and treatment strategies.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient with histologically-confirmed cancer
* Patient harboring a rare actionable fusion (see Appendix 1),
* Availability of clinical and demographic data, information on treatment and clinical outcome.
* Adult, ≥18 years old,
* Patient should understand, sign and date the written voluntary informed consent form.

Exclusion Criteria:

-

Where this trial is running

Graz and 40 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions CancerCancer MetastaticNTRK Gene Fusion OverexpressionNTRK Family Gene MutationATIC-ALK Fusion Protein ExpressionALK Fusion Protein ExpressionBCR-FGFR1 Fusion Protein ExpressionROS1 Gene Translocation
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.